ArticleInternational journal of reproductive biomedicine2026
Hydroxytyrosol protects sperm viability and DNA integrity in human asthenoteratozoospermia during incubation: An experimental study.
Article in International journal of reproductive biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asthenoteratozoospermia (AT), marked by poor sperm motility and abnormal morphology, is a major cause of male infertility. During semen handling, AT samples generate high reactive oxygen species (ROS) levels, increasing oxidative stress and sperm damage. Objective: This study investigated the effects of hydroxytyrosol (HT), a natural antioxidant, on sperm quality and ROS levels in AT samples during incubation. Materials and Methods: This experimental study was conducted in 2 phases. In phase I, 20 AT samples were divided into 5 groups (0, 25, 50, 75, and 100 μg/mL HT) and incubated for 30, 45, and 60 min to determine optimal conditions based on sperm motility and viability. In phase II, another 20 AT samples were treated with 25 and 50 μg/mL HT for 30 min. Sperm mitochondrial membrane potential, intracellular ROS, DNA fragmentation, and lipid peroxidation were evaluated. Results: Sperm motility decreased after incubation; however, treatment with HT maintained motility, although the difference was not statistically significant. Similarly, sperm viability declined following incubation compared to the baseline. 25 μg/mL HT significantly preserves sperm viability after 30 min compared to 0 μg/mL HT (p = 0.02). Incubation significantly increased DNA fragmentation; however, at both 25 and 50 μg/mL HT, DNA fragmentation remained comparable to pre-incubation levels. No significant effects were observed on lipid peroxidation, ROS levels, or mitochondrial membrane potential. Conclusion: Incubation of AT sperm with HT for 30 min preserved sperm viability and reduced DNA damage, suggesting that HT may serve as a beneficial antioxidant in assisted reproductive technologies for men with AT by minimizing oxidative stress-related sperm damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.